info@seagull-health.com
SeagullHealth
语言:
search
new
What kinds of diseases is Sparsentan(Filspari) suitable for?
502
Article source: Seagull Pharmacy
Jun 20, 2025

The main ingredient of Filspari is Sparsentan, which acts on ETAR and AT1R, can reduce the level of proteinuria in patients, and has the "orphan drug title" for the treatment of IgA nephropathy.

What kinds of diseases is Sparsentan(Filspari) suitable for?

Sparsentan has the effect of antagonizing type A endothelin receptor (ETAR) and angiotensin type II type 1 receptor (AT1R), which is suitable for adult patients with primary immunoglobulin A nephropathy (IgAN), and Sparsentan achieves the purpose of treating diseases by antagonizing type A endothelin receptor (ETAR) and angiotensin type II type 1 receptor (AT1R).

Sepasentan is not currently marketed in China, patients can consult and purchase through the overseas medical consulting service platform if necessary, pay attention to the medication according to the doctor's medication guidance and treatment plan when purchasing and using, follow the doctor's instructions, and if there are any adverse reactions in the process of medication, it is necessary to communicate with the doctor in time so as to adjust the medication regimen and dosage.

Recommended dosage of Sparsentan(Filspari)

The following is the recommended dosage of sparsentan under normal circumstances, which is for the patient's reference only, and the specific dosage and dose adjustment need to be carried out according to the specific situation of the patient, during the treatment process, the patient should follow the doctor's advice, and regularly review and evaluate.

Starting dose

For patients starting Sparsentan, the recommended starting dose is 200mg orally once daily. The purpose of this dose is to help the patient gradually adjust to the drug and observe how well it can tolerate it.

Dose adjustment

On the 14th day of medication, the doctor will adjust the dose to 400mg once a day according to the patient's tolerance and response to efficacy.

Restart after the interruption of the medication process

When patients need to restart treatment after discontinuation of Sparsentan, it is recommended to start with a dose of 200mg once daily and gradually increase the dose to 400 mg once daily after 14 days. This can help reduce adverse effects due to a sudden increase in medications.

When purchasing medicines, it is important to ensure that the purchase channel is regular. It is recommended to choose a reputable and regular pharmacy or medical institution to purchase to ensure the quality of the medicine. Avoid buying medicines from unknown sources to avoid encountering counterfeit and shoddy products that can harm your health. Choose formal channels carefully.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Sparsentan(Filspari)
Sparsentan(Filspari)
Adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk...
WeChat Scan
Free Inquiry
Recommended Articles
Indications for Sparsentan
Sparsentan, also known as Filspari, is an innovative drug with specific therapeutic effects. This article will elaborate on the indications, drug interactions and basic pharmacological effects of Spar...
Things to note when using tazemetostat
Tazemetostat is a new generation of oral tyrosine kinase inhibitors, designed specifically for a variety of hematologic and solid-related diseases. By accurately blocking abnormal cell signaling ...
How to use Tazemetostat and its precautions
Tazemetostat is an innovative targeted therapeutic drug, mainly used to treat specific types of related diseases. By accurately inhibiting the key signaling pathways in the growth of cells in rel...
Things to note when using Tazemetostat
Tazemetostat is an innovative targeted therapeutic drug, mainly used to treat certain specific types of hemologic diseases, such as multiple bone marrow-related diseases. By accurately inhibiting...
What are the suitable populations for Sparsentan(Filspari)?
Sparsentan(Filspari) is a white or off-white oval film-coated tablet, is a unique single-molecule drug, used in clinical treatment of primary immunoglobulin A nephropathy (IgAN), has the title of...
Guidelines for the use of Sparsentan
Sparsentan is a drug used to treat specific types of kidney disease, especially in patients with primary immunoglobulin A nephropathy (IgAN). This article will explore how the drug is used, how well i...
How to use Sparsentan?
Sparsentan is a drug used to treat specific types of kidney disease, especially in patients with primary immunoglobulin A nephropathy (IgAN). This article will introduce in detail how to use this drug...
Guidelines for the use of Sparsentan
Sparsentan is a drug used to treat primary immunoglobulin A nephropathy (IgAN) with a risk of rapid disease progression, improving the condition by lowering the patient's proteinuria levels. This ...
Related Articles
Dosage and Administration of Sparsentan (Filspari)
Sparsentan (Filspari) is a dual antagonist of endothelin and angiotensin II receptors, which was first approved in the United States in 2023. This medication is mainly used to slow the decline of rena...
What are the Indications of Sparsentan (Filspari)?
Sparsentan (Filspari) is a new type of oral medication, which was first approved for marketing in the United States in 2023. It is a dual endothelin and angiotensin II receptor antagonist, suitable fo...
What Are the Purchase Channels for Sparsentan (Filspari)?
Sparsentan (Filspari) is a novel dual endothelin and angiotensin II receptor antagonist, which holds significant clinical value in delaying the decline of renal function in adult patients with primary...
Things to note about Sparsentan
Sparsentan is clinically suitable for adult patients with primary immunoglobulin A nephropathy (IgAN). It has the title of "orphan drug" for the treatment of IgA nephropathy. Many patie...
What should I pay attention to when taking Filspari?
Filspari is clinically suitable for adult patients with primary immunoglobulin A nephropathy (IgAN). It has the title of "orphan drug" for the treatment of IgA nephropathy. Many patient...
Side effects of Sparsentan
Sparsentan is a drug used to treat specific types of kidney disease, especially in patients with primary immunoglobulin A nephropathy (IgAN). This article will provide detailed descriptions of po...
How to relieve side effects of Sparsentan?
Sparsentan is a drug used to treat specific types of kidney disease, especially in patients with primary immunoglobulin A nephropathy (IgAN). This article will provide detailed descriptions on ho...
Sparsentan side effects and precautions
Sparsentan is a drug used to treat primary immunoglobulin A nephropathy (IgAN) by targeting ETAR and AT1R receptors to reduce proteinuria levels.Sparsentan side effects and precautionsSparse...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved